Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
, , ,
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses
Storage and stability Proper storage preserves peptide integrity
Great medication and service
